文献速递白血病

LIM激酶在急性髓系白血病中的必要性

Requirement for LIM kinases in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2020-06-26

该研究通过高通量RNA干扰筛选在急性髓系白血病(AML)细胞系中鉴定LIMK1为潜在新靶点。高LIMK1表达与AML患者较短生存显著相关,并与FLT3突变、KMT2A重排及HOX基因表达升高同时出现。RNAi和CRISPR-Cas9抑制及药理抑制LIMK1及其同源物LIMK2可减少集落形成并因细胞周期进展减慢而降低KMT2A重排AML细胞系和患者来源异种移植(PDX)样本的增殖,伴随提示髓系分化的形态学改变。转录组分析显示LIMK1抑制后多个肿瘤抑制基因上调、HOXA9靶基因和有丝分裂相关基因下调。LIMK与CDK6相互调节,添加CDK6抑制剂哌柏西利进一步增强LIMK抑制的抗增殖效果。这些数据提示LIMK是AML治疗的有希望靶点。

要点

  • 高通量RNAi筛选在AML细胞系中鉴定LIMK1为潜在新靶点。
  • 高LIMK1表达与AML患者较短生存显著相关。
  • 抑制LIMK1/LIMK2减少KMT2A重排AML细胞系和PDX样本集落形成与增殖。

核心结论

  • 这些数据提示LIMK是AML治疗的有希望靶点。

研究设计与样本

  • 研究在AML细胞系中进行高通量RNA干扰筛选,并使用RNAi和CRISPR-Cas9介导的抑制以及药理抑制,在KMT2A重排AML细胞系和患者来源异种移植(PDX)样本中评估LIMK1和LIMK2的功能。

主要发现

  • 高LIMK1表达与AML患者较短生存显著相关,并与FLT3突变、KMT2A重排及HOX基因表达升高同时出现。
  • RNAi和CRISPR-Cas9介导的抑制以及药理抑制LIMK1及其同源物LIMK2减少集落形成并因细胞周期进展减慢而降低KMT2A重排AML细胞系和PDX样本的增殖,伴随提示髓系分化的形态学改变。
  • 转录组分析显示LIMK1抑制后多个肿瘤抑制基因上调以及HOXA9靶基因和有丝分裂相关基因下调。
  • 观察到LIMK与CDK6相互调节,添加CDK6抑制剂哌柏西利进一步增强LIMK抑制的抗增殖效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive disease for which only few targeted therapies are available. Using high-throughput RNA interference (RNAi) screening in AML cell lines, we identified LIM kinase 1 (LIMK1) as a potential novel target for AML treatment. High LIMK1 expression was significantly correlated with shorter survival of AML patients and coincided with FLT3 mutations, KMT2A rearrangements, and elevated HOX gene expression. RNAi- and CRISPR-Cas9-mediated suppression as well as pharmacologic inhibition of LIMK1 and its close homolog LIMK2 reduced colony formation and decreased proliferation due to slowed cell-cycle progression of KMT2A-rearranged AML cell lines and patient-derived xenograft (PDX) samples. This was accompanied by morphologic changes indicative of myeloid differentiation. Transcriptome analysis showed upregulation of several tumor suppressor genes as well as downregulation of HOXA9 targets and mitosis-associated genes in response to LIMK1 suppression, providing a potential mechanistic basis for the anti-leukemic phenotype. Finally, we observed a reciprocal regulation between LIM kinases (LIMK) and CDK6, a kinase known to be involved in the differentiation block of KMT2A-rearranged AML, and addition of the CDK6 inhibitor palbociclib further enhanced the anti-proliferative effect of LIMK inhibition. Together, these data suggest that LIMK are promising targets for AML therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jensen P, Carlet M, Schlenk RF, et al. Requirement for LIM kinases in acute myeloid leukemia. Leukemia. 2020. PMID: 32591645. doi:10.1038/s41375-020-0943-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。